• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Travere Therapeutics, Inc.

< Previous 1 2 Next >
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 13, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
November 12, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
November 04, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 21, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers ASX CSLLY TVTX
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 26, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 05, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
August 22, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
August 06, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Second Quarter 2024 Financial Results
August 01, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Report Second Quarter 2024 Financial Results
July 25, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 08, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 09, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 06, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 29, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers ASX:CSL CSLLY TVTX
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
April 04, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 03, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
March 11, 2024
From Travere Therapeutics, Inc.
Via GlobeNewswire
Tickers TVTX
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap